JZL184
CAS No. 1101854-58-3
JZL184( JZL184 | JZL 184 | JZL-184 )
Catalog No. M17810 CAS No. 1101854-58-3
JZL 184 is a potent and selective inhibitor of MAGL with IC50 of 8 nM and 4 μM for inhibition of MAGL and FAAH in mouse brain membranes respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 31 | In Stock |
|
10MG | 49 | In Stock |
|
25MG | 104 | In Stock |
|
50MG | 197 | In Stock |
|
100MG | 357 | In Stock |
|
200MG | 482 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJZL184
-
NoteResearch use only, not for human use.
-
Brief DescriptionJZL 184 is a potent and selective inhibitor of MAGL with IC50 of 8 nM and 4 μM for inhibition of MAGL and FAAH in mouse brain membranes respectively.
-
DescriptionJZL184 is highly selective, and potent MAGL inhibitor ( monoacylglycerol lipase inhibitor). JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome. JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. JZL184 also suppresses inflammatory pain in the mouse carrageenan model.
-
In VitroJZL 184 displays IC50 values of 8 nM and 4 μM for blockade of 2-AG and oleamide (FAAH substrate) hydrolysis in brain membranes, respectively. Comparable inhibitory effects are observed with recombinant MAGL and FAAH when expressed in COS7 cells.
-
In VivoJZL 184 (4-40 mg/kg; intraperitoneal injection; once; C57Bl/6 mice) treatment produces a rapid and sustained blockade of brain 2-AG hydrolase activity in mice, resulting in 8-fold elevations in endogenous 2-AG levels that are maintained for at least 8 h. JZL 184-treated mice shows a remarkable array of CB1-dependent behavioral effects, including analgesia, hypomotility, and hypothermia.JZL 184 prolongs depolarization-induced suppression of excitation (DSE) in Purkinje neurons in cerebellar slices and DSE inhibition (DSI) in CA1 pyramidal neurons in hippocampal slices. JZL 184 produces greater enhancement of DSE/DSI in mouse neurons than that in rat neurons. Animal Model:Male C57Bl/6 mice (6-8 weeks old, 20-26 g) Dosage:4 mg/kg, 8 mg/kg, 16 mg/kg, 40 mg/kg Administration:Intraperitoneal injection; once Result:Produced a rapid and sustained blockade of brain 2-AG hydrolase activity in mice, resulting in 8-fold elevations in endogenous 2-AG levels that were maintained for at least 8 h.
-
SynonymsJZL184 | JZL 184 | JZL-184
-
PathwayOthers
-
TargetOther Targets
-
RecptorMAGL
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number1101854-58-3
-
Formula Weight520.49
-
Molecular FormulaC27H24N2O9
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 35 mg/mL; 67.24 mM
-
SMILESOC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+](=O)[O-])(c1ccc2OCOc2c1)c1ccc2OCOc2c1
-
Chemical Name4-nitrophenyl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate.
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Long JZ, et al. Nat Chem Biol, 2009, 5(1), 37-44.
molnova catalog
related products
-
Ninhydrin
Ninhydrin is a chromogenic analytical probe for the quantification of proteins and amino acids.
-
Bretazenil
Bretazenil is a GABAA benzodiazepine site partial agonist. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2.
-
VPC-18005
VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.